Joint Motion For Abilify MDL Will Be Heard Sept. 29 By Judicial Panel

(August 12, 2016, 1:26 PM EDT) -- WASHINGTON, D.C. — The Judicial Panel on Multidistrict Litigation (JPMDL) will hear arguments on Sept. 29 on a request by plaintiffs and defendants to centralize federal lawsuits alleging that Abilify causes compulsive gambling, according to an Aug. 11 panel order (In Re: Abilify [Aripiprazole] Products Liability Litigation, MDL Docket No. 2734, JPMDL).

Abilify is approved to treat schizophrenia, bipolar I disorder and major depressive disorder. In May, the Food and Drug Administration said it will require Abilify's warning label to warn of the risk of "compulsive...
To view the full article, register now.